340B Drug Discount Program sales hit $100 billion in 2025, up 22.8% year over year

The Health Resources and Services Administration reported that purchases under the 340B discount program reached $100 billion in 2025, a 22.8% rise from 2024.

Expensive medicines made up a growing share of the program, accounting for $61.9 billion, or roughly 62% of total 340B spending.

The top spenders were Merck’s Keytruda immunotherapy at about $8.9 billion and Gilead’s HIV drug Biktarvy at more than $4.47 billion.

The 340B program requires manufacturers to provide discounts of roughly 25%‑50% to eligible hospitals and clinics that serve low‑income patients, and the continued growth highlights the increasing cost burden of high‑price therapies within the discount framework.